Previous evidence suggests that SLPI may be a novel biomarker and target candidate for acute kidney injury (AKI), indicated by upregulation of SLPI mRNA levels in AKI allografts as well as elevated protein levels of SLPI in plasma and urine of AKI patients [50]. This evidence concerns the gene SLPI and acute kidney injury.